Incyte Announces $422 Million Private Placement

Feb 24, 2000

Premium

P

ALO ALTO, Calif.--Incyte Pharmaceuticals said it has entered into a definitive purchase agreement for the sale of two million shares of newly issued common stock to selected institutional investors for $422 million. Purchase price will be $211 per share. The company said net proceeds will be used for working capital and general corporate purposes as well as to make strategic investments, acquire or license technology or products, or acquire complementary businesses.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Drive Away the Flies

University of California, San Diego, researchers have developed a gene drive to control a fruit-destroying fly.

Fewer Transfusions Needed

A new study of a β-thalassemia gene therapy appears promising, according to NPR.

This Week in Nature

In Nature this week: hair color genes, hybridization between 13-year and 17-year cicadas, and more.

Alteration Here and There to Win

Futurism writes that gene doping could be the next generation of cheating in sports.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu